Top entities: Aurisco Pharmaceutical, United States — Food and Drug Administration, China, Ming Guoping, Li Jinliang.

What category does this event fall under?

Regulatory — classified as regulatory approval.

What is the sentiment of coverage?

Aggregate sentiment score: 60 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This is an active story, last updated Aug 12, 2026. Coverage continues to evolve.

Regulatory regulatory approval

Aurisco passes USFDA generic oligonucleotide inspection

Q: When did this event occur?

First reported Aug 12, 2026; last updated Aug 12, 2026.

Q: What is the market impact?

General. The approval positions Aurisco as a pioneer in generic oligonucleotide manufacturing, potentially increasing its market share and revenue from generic versions of blockbuster drugs.

Analysis based on 7 articles · First reported Aug 12, 2026 · Last updated Aug 12, 2026

Sentiment

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The approval positions Aurisco as a pioneer in generic oligonucleotide manufacturing, potentially increasing its market share and revenue from generic versions of blockbuster drugs. It may also pressure originator companies by enabling cheaper alternatives, affecting the broader pharmaceutical market.

Pharmaceuticals Biotechnology

Event Summary

Aurisco Pharmaceutical, a Chinese manufacturer of oligonucleotides and peptides, announced that its Yangzhou site passed a USFDA pre-approval inspection for Inclisiran Sodium, making it the first generic oligonucleotide API manufacturer in the world to receive such approval. The inspection, conducted from June 15-19, 2026, covered cGMP compliance for oligonucleotides, GLP-1 peptides, and small molecules. The USFDA issued an EIR letter confirming that Aurisco addressed all observations with an approved CAPA plan. This milestone opens the door for future generic oligonucleotides such as Inclisiran, Vutrisiran, Nusinersen, and Eplontersen. Aurisco's site had previously been inspected by the USFDA in 2023. The company offers both CDMO services and generic APIs.

Key Actions

100 United States — Food and Drug Administration inspected Aurisco Pharmaceutical

Entities Involved

priv

Aurisco Pharmaceutical

Aurisco is the central entity, achieving a world-first USFDA approval for generic oligonucleotide manufacturing, which enhances its reputation and market prospects.

Importance 100.0 Sentiment 80.0

govactor

United States — Food and Drug Administration

The USFDA conducted and approved the inspection, playing a regulatory role that validates Aurisco's compliance and sets a precedent for future generic oligonucleotide approvals.

Importance 90.0 Sentiment 0.0

cnt

China

China is the location of Aurisco's manufacturing site, and this approval highlights the country's growing capabilities in advanced pharmaceutical manufacturing.

Importance 40.0 Sentiment 20.0

per

Ming Guoping

Ming Guoping, as site GM, commented on the significance of the inspection, representing Aurisco's leadership in this achievement.

Importance 30.0 Sentiment 10.0

per

Li Jinliang

Li Jinliang, as Board Director, expressed support and highlighted the potential for affordable oligonucleotides, reinforcing the company's strategic direction.

Importance 30.0 Sentiment 10.0

Relationships

United States — Food and Drug Administration related ↔ China

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard